D. Drummond

发表

Current status of pH-sensitive liposomes in drug delivery.

M. Zignani, J. Leroux, D. Drummond, 2000, Progress in lipid research.

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

John W. Park, D. Drummond, C. Noble, 2008, Journal of pharmaceutical sciences.

Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases.

J. Marks, D. Drummond, M. Hayes, 2006, Biochimica et biophysica acta.

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

U. Nielsen, C. Benz, John W. Park, 2006, Cancer research.

Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics

Douglas A. Lauffenburger, Andrew Sawyer, Andreas Raue, 2018, Cell reports.

Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models.

F. Chen, C. James, John W. Park, 2013, Nanomedicine.

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.

C. Mamot, John W. Park, D. Drummond, 2005, Cancer research.

Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

D. Papahadjopoulos, D. Drummond, D. Kirpotin, 1999, Pharmacological reviews.

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.

W. Kamoun, Z. Huang, D. Drummond, 2019, Journal of controlled release : official journal of the Controlled Release Society.

Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain

Ryuta Saito, Mitchel S. Berger, Krystof S. Bankiewicz, 2005, Experimental Neurology.

Extensive Distribution of Liposomes in Rodent Brains and Brain Tumors Following Convection-Enhanced Delivery

M. Berger, C. Mamot, John W. Park, 2004, Journal of Neuro-Oncology.

Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: Implications for local drug delivery

M. Berger, John W. Park, D. Drummond, 2006, Journal of Neuroscience Methods.

In vivo Multiple Anticancer Drugs Immunoliposomes Significantly Enhance the Efficacy of Targeted − Epidermal Growth Factor Receptor

C. Mamot, John W. Park, D. Drummond, 2005 .

Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells1

C. Mamot, John W. Park, J. Marks, 2003 .

Epidermal Growth Factor Receptor ( EGFR )-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR-and EGFRvIII-overexpressing Tumor Cells 1

C. Mamot, John W. Park, J. Marks, 2003 .

Development of a highly stable and targetable nanoliposomal formulation of topotecan.

Ceirin M. Connolly-Ingram, C. Benz, B. Hann, 2010, Journal of controlled release : official journal of the Controlled Release Society.

Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.

M. Berger, John W. Park, D. Drummond, 2014, Nanomedicine.

Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.

M. Berger, John W. Park, D. Drummond, 2006, Cancer research.

Enhanced Toxicity for Mice of Combinations of Bacterial Lipopolysaccharide and Vincristine

S. Bradley, D. Drummond, A. Munson, 1976, Antimicrobial Agents and Chemotherapy.

Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”

Rachael M. Crist, V. Shah, D. Crommelin, 2019, The AAPS Journal.

Characterization of biofilm formation by clinical isolates of Mycobacterium avium.

Martin Wu, L. Bermudez, D. Drummond, 2003, Journal of medical microbiology.

Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.

John W. Park, T. Kawaguchi, D. Drummond, 2007, Neuro-oncology.

Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts 1 Neuro-oNcology

John W. Park, T. Kawaguchi, D. Drummond, 2006 .

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine

C. Benz, John W. Park, J. Marks, 2009, Cancer Chemotherapy and Pharmacology.

Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models

E. Tam, W. Kamoun, Z. Huang, 2019, Molecular Cancer Therapeutics.

Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle

U. Nielsen, A. Lugovskoy, Y. Jiao, 2015, mAbs.

Intraliposomal Trapping Agents for Improving In Vivo Liposomal Drug Formulation Stability

John W. Park, D. Drummond, C. Noble, 2006, Liposome Technology.

A novel assay for monitoring internalization of nanocarrier coupled antibodies

U. Nielsen, J. Marks, D. Drummond, 2006, BMC Immunology.

Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging

M. Berger, M. Wendland, C. Mamot, 2004, Cancer Research.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

W. Kamoun, J. Marks, A. Lugovskoy, 2019, Nature Biomedical Engineering.

Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.

B. Hendriks, G. Sahagian, W. Kamoun, 2019, Nanomedicine : nanotechnology, biology, and medicine.

Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics

A. Lugovskoy, D. Drummond, D. Kirpotin, 2022, mAbs.

Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting

J. Marks, A. Lugovskoy, Y. Jiao, 2017, mAbs.

A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma

Jennie W. Taylor, Susan M. Chang, M. Prados, 2017, Cancer Chemotherapy and Pharmacology.

Convection-enhanced delivery of liposomal doxorubicin in intracranial brain tumor xenografts

M. Berger, John W. Park, T. Kawaguchi, 2006, Targeted Oncology.

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer

B. Hendriks, J. Fitzgerald, P. Bunn, 2017, Anti-cancer drugs.

New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model

S. Mueller, D. Drummond, C. Noble, 2018, Journal of Neuro-Oncology.

Improved Pharmacokinetics and Efficacy of a Highly Stable Nanoliposomal Vinorelbine

John W. Park, D. Drummond, C. Noble, 2009, Journal of Pharmacology and Experimental Therapeutics.

Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI)

U. Nielsen, J. Fitzgerald, W. Kamoun, 2014 .

Convection-enhanced delivery of Ls-TPT enables an effective , continuous , low-dose chemotherapy against malignant glioma xenograft model 1

M. Berger, John W. Park, D. Drummond, 2006 .

Phosphatidylserine binding alters the conformation and specifically enhances the cofactor activity of bovine factor Va.

X. Zhai, D. Drummond, B. Lentz, 2002, Biochemistry.

Liposome-based approaches to overcome anticancer drug resistance.

C. Mamot, John W. Park, D. Drummond, 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

B. Schoeberl, U. Nielsen, E. Pace, 2018, Clinical Cancer Research.

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

John W. Park, D. Drummond, C. Noble, 2006, Cancer research.

In vitro characterization of a novel polymeric-based pH-sensitive liposome system.

J. Leroux, M. Zignani, D. Drummond, 2000, Biochimica et biophysica acta.

The effects of amphotericin B, fluconazole and miconazole on neutrophil and lymphocyte function in a guinea pig model.

D. Drummond, J. McCormack, L. Whitman, 1995, The Journal of antimicrobial chemotherapy.

Clinical development of histone deacetylase inhibitors as anticancer agents.

C. Benz, G. Scott, D. Drummond, 2005, Annual review of pharmacology and toxicology.

Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery

C. Benz, John W. Park, J. Marks, 2006, Gene Therapy.

N-isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles.

E. Roux, D. Drummond, J. Leroux, 2001, Journal of controlled release : official journal of the Controlled Release Society.

HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.

U. Nielsen, B. Hendriks, P. Zandstra, 2012, Toxicology and applied pharmacology.

Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic

C. Morrison, M. Mino‐Kenudson, W. Bshara, 2018, Pharmaceutics.

Canine spontaneous glioma: a translational model system for convection-enhanced delivery.

M. Berger, John W. Park, D. Drummond, 2010, Neuro-oncology.

Synthesis and characterization of N-acylated, pH-sensitive 'caged' aminophospholipids.

D. Drummond, D C Drummond, D. Daleke, 1995, Chemistry and physics of lipids.

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer

J. Marks, D. Drummond, B. Liu, 2007, Journal of Molecular Medicine.

Drug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan.

Z. Huang, D. Drummond, C. Noble, 2022, Journal of pharmaceutical sciences.

Development of ligand-targeted liposomes for cancer therapy

C. Benz, C. Mamot, John W. Park, 2004, Expert opinion on therapeutic targets.

Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.

U. Nielsen, J. Fitzgerald, D. Drummond, 2014, Cancer research.

Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.

John W. Park, T. Kawaguchi, D. Drummond, 2007, Neuro-oncology.

Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

M. Berger, John W. Park, D. Drummond, 2006, Neuro-oncology.

Title: Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Pro-drug Conversion

U. Nielsen, J. Fitzgerald, D. Drummond, 2014 .

Liposome targeting to tumors using vitamin and growth factor receptors.

C. Benz, D. Drummond, D. Kirpotin, 2000, Vitamins and hormones.

Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

T. Triche, J. Fitzgerald, D. Drummond, 2015, Clinical Cancer Research.

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Udo Greiser, C. Mamot, John W. Park, 2003, Cancer research.

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

R. Korn, B. Hendriks, N. Raghunand, 2017, Clinical Cancer Research.

Building and characterizing antibody-targeted lipidic nanotherapeutics.

Yu Zhou, Ulrik B Nielsen, Zhaohua Huang, 2012, Methods in enzymology.

Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.

Kevin C Weng, F. Chen, Donghui Wang, 2008, Nano letters.

Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells

C. Benz, B. Liu, J. Marks, 2007, Molecular Cancer Therapeutics.

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

Yu Zhou, G. Adams, J. Marks, 2007, Journal of molecular biology.

Preclinical Manufacture of Anti‐HER2 Liposome‐Inserting, scFv‐PEG‐Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis

John W. Park, J. Marks, D. Drummond, 2008, Biotechnology progress.

Preclinical Manufacture of an Anti‐HER2 scFv‐PEG‐DSPE, Liposome‐Inserting Conjugate. 1. Gram‐Scale Production and Purification

Jianwei Zhu, Jianwei Zhu, John W. Park, 2008, Biotechnology progress.

Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes

C. Benz, Donghui Wang, G. Scott, 2005, Clinical Cancer Research.

Liposomal Drug Delivery Systems for Cancer Therapy

C. Benz, John W. Park, D. Drummond, 2004 .

Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

M. Prados, C. James, John W. Park, 2011, Neuro-oncology.

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity

M. Muda, A. Raue, E. Tam, 2019, Science Translational Medicine.

Preclinical Activity of MM-398 , Nanoliposomal Irinotecan ( nal-IRI ) , in Ewing ' s Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN 11 Expression

T. Triche, J. Fitzgerald, D. Drummond, 2015 .

Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.

B. Liu, Lan Huang, J. Marks, 2007, Molecular immunology.

Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.

M. Berger, M. Prados, C. James, 2013, Neuro-oncology.

Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation.

Yoji Yamashita, Mitchel S Berger, M. Berger, 2008, Journal of neurosurgery.

Effect of bacterial lipopolysaccharide, lipid A, and concanavalin A on lethality of 5-fluorouracil for mice.

S. Bradley, D. Drummond, A. Munson, 1975, Toxicology and applied pharmacology.

Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies

B. Liu, D. Drummond, D. Kirpotin, 2008, Molecular Cancer Therapeutics.

Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway

Birgit Schoeberl, Michael B Yaffe, Millie Shah, 2018, Science Signaling.

Abstract 2491: Engineering and preclinical activity of MM-201, a best-in-class TRAIL receptor agonist

E. Tam, D. Drummond, A. Koshkaryev, 2019, Molecular and Cellular Biology / Genetics.

Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer

B. Schoeberl, M. Mino‐Kenudson, A. Lugovskoy, 2019, Scientific Reports.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

W. Kamoun, J. Marks, A. Lugovskoy, 2019, Nature Biomedical Engineering.

Discovery of internalizing antibodies to basal breast cancer cells

C. Benz, C. Yau, John W. Park, 2018, Protein engineering, design & selection : PEDS.

Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”

Rachael M. Crist, V. Shah, D. Crommelin, 2019, The AAPS Journal.

Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation.

C. Benz, J. Cohen, J. Marks, 2006, Molecular pharmaceutics.

Abstract P3-14-09: Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines

C. Benz, B. Hendriks, John W. Park, 2010 .

Development of novel liposomal and receptor tyrosine kinase-targeted immunoliposomal vinorelbine formulations with improved drug retention

C. Mamot, John W. Park, J. Marks, 2005 .

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

C. Mamot, John W. Park, J. Marks, 2003, Cancer research.

Liposomal Drug Delivery Systems for Cancer Therapy

C. Benz, John W. Park, D. Drummond, 2004 .

Abstract 750: Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Clinical translation:

W. Kamoun, J. Marks, A. Lugovskoy, 2016 .

Abstract 5771: Targeting EphA2 in bladder cancer using a novel antibody-directed nanotherapeutic

C. Morrison, W. Bshara, W. Kamoun, 2018, Experimental and Molecular Therapeutics.